Four hundred fifty volunteers participated in a placebo-controlled, double-blind, randomized trial of the prophylactic effects of rimantadine and amantadine during an outbreak of influenza A. The subjects received drugs orally at a dose of 100 mg twice a day for six weeks. Influenza-like illness occurred in 41 per cent of the subjects receiving placebo but in only 14 per cent of those receiving rimantadine and 9 per cent of these receiving amantadine (P less than 0.001 for either drug vs. placebo). Laboratory-documented influenza occurred in 21 per cent of placebo recipients, 3 per cent of rimantadine recipients, and 2 per cent of amantadine recipients (P less than 0.001). These findings represent efficacy rates of 85 per cent for rimantadine and 91 per cent for amantadine, as compared with placebo. More recipients of amantadine (13 per cent) than recipients of rimantadine (6 per cent; P less than 0.05) or placebo (4 per cent; P less than 0.01) withdrew from the study because of central-nervous-system side effects. On the basis of this study, rimantadine appears to be the drug of choice for the prophylaxis of influenza A.
This article has been cited by other articles:
Hu, J., Fu, R., Cross, T. A.
(2007). The Chemical and Dynamical Influence of the Anti-Viral Drug Amantadine on the M2 Proton Channel Transmembrane Domain. Biophys. J
93: 276-283
[Abstract][Full Text]
Tsiodras, S., Mooney, J. D, Hatzakis, A.
(2007). Role of combination antiviral therapy in pandemic influenza and stockpiling implications. BMJ
334: 293-294
[Full Text]
Bright, R. A., Shay, D. K., Shu, B., Cox, N. J., Klimov, A. I.
(2006). Adamantane Resistance Among Influenza A Viruses Isolated Early During the 2005-2006 Influenza Season in the United States. JAMA
295: 891-894
[Abstract][Full Text]
(2005). Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. Am. J. Respir. Crit. Care Med.
171: 388-416
[Full Text]
Kotloff, R. M., Ahya, V. N., Crawford, S. W.
(2004). Pulmonary Complications of Solid Organ and Hematopoietic Stem Cell Transplantation. Am. J. Respir. Crit. Care Med.
170: 22-48
[Abstract][Full Text]
Rothberg, M. B., Bellantonio, S., Rose, D. N.
(2003). Management of Influenza in Adults Older than 65 Years of Age: Cost-Effectiveness of Rapid Testing and Antiviral Therapy. ANN INTERN MED
139: 321-329
[Abstract][Full Text]
Oliveira, E. C., Lee, B., Colice, G. L.
(2003). Influenza in the Intensive Care Unit. J Intensive Care Med
18: 80-91
[Abstract]
Stiver, G.
(2003). The treatment of influenza with antiviral drugs. CMAJ
168: 49-57
[Abstract][Full Text]
Lee, P. Y., Matchar, D. B., Clements, D. A., Huber, J., Hamilton, J. D., Peterson, E. D.
(2002). Economic Analysis of Influenza Vaccination and Antiviral Treatment for Healthy Working Adults. ANN INTERN MED
137: 225-231
[Abstract][Full Text]
Furuta, Y., Takahashi, K., Fukuda, Y., Kuno, M., Kamiyama, T., Kozaki, K., Nomura, N., Egawa, H., Minami, S., Watanabe, Y., Narita, H., Shiraki, K.
(2002). In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705. Antimicrob. Agents Chemother.
46: 977-981
[Abstract][Full Text]
Stephenson, I., Nicholson, K.G.
(2001). Influenza: vaccination and treatment. Eur Respir J
17: 1282-1293
[Abstract][Full Text]
Iwahashi, J., Tsuji, K., Ishibashi, T., Kajiwara, J., Imamura, Y., Mori, R., Hara, K., Kashiwagi, T., Ohtsu, Y., Hamada, N., Maeda, H., Toyoda, M., Toyoda, T.
(2001). Isolation of Amantadine-Resistant Influenza A Viruses (H3N2) from Patients following Administration of Amantadine in Japan. J. Clin. Microbiol.
39: 1652-1653
[Abstract][Full Text]
Couch, R. B.
(2000). Prevention and Treatment of Influenza. NEJM
343: 1778-1787
[Full Text]
Cifu, A., Levinson, W.
(2000). Influenza. JAMA
284: 2847-2849
[Full Text]
Monto, A. S., Gravenstein, S., Elliott, M., Colopy, M., Schweinle, J.
(2000). Clinical Signs and Symptoms Predicting Influenza Infection. Arch Intern Med
160: 3243-3247
[Abstract][Full Text]
Keyser, L. A., Karl, M., Nafziger, A. N., Bertino, J. S. Jr
(2000). Comparison of Central Nervous System Adverse Effects of Amantadine and Rimantadine Used as Sequential Prophylaxis of Influenza A in Elderly Nursing Home Patients. Arch Intern Med
160: 1485-1488
[Abstract][Full Text]
Fenton, R. J., Morley, P. J., Owens, I. J., Gower, D., Parry, S., Crossman, L., Wong, T.
(1999). Chemoprophylaxis of Influenza A Virus Infections, with Single Doses of Zanamivir, Demonstrates that Zanamivir Is Cleared Slowly from the Respiratory Tract. Antimicrob. Agents Chemother.
43: 2642-2647
[Abstract][Full Text]
Hayden, F. G., Atmar, R. L., Schilling, M., Johnson, C., Poretz, D., Paar, D., Huson, L., Ward, P., Mills, R. G., The Oseltamivir Study Group,
(1999). Use of the Selective Oral Neuraminidase Inhibitor Oseltamivir to Prevent Influenza. NEJM
341: 1336-1343
[Abstract][Full Text]
Monto, A. S., Robinson, D. P., Herlocher, M. L., Hinson, J. M. Jr, Elliott, M. J., Crisp, A.
(1999). Zanamivir in the Prevention of Influenza Among Healthy Adults: A Randomized Controlled Trial. JAMA
282: 31-35
[Abstract][Full Text]
Stephenson, I., Nicholson, K. G.
(1999). Chemotherapeutic control of influenza. J Antimicrob Chemother
44: 6-10
[Full Text]
Balfour, H. H.
(1999). Antiviral Drugs. NEJM
340: 1255-1268
[Full Text]
Drinka, P. J., Gravenstein, S., Schilling, M., Krause, P., Miller, B. A., Shult, P.
(1998). Duration of Antiviral Prophylaxis During Nursing Home Outbreaks of Influenza A: A Comparison of 2 Protocols. Arch Intern Med
158: 2155-2159
[Abstract][Full Text]
Paap, C. M., Nahata, M. C.
(1991). Treatment of Common Respiratory Tract Infections. Journal of Pharmacy Practice
4: 158-169
Dolin, R
(1985). Antiviral chemotherapy and chemoprophylaxis. Science
227: 1296-1303
[Abstract]
Previous
